Basit öğe kaydını göster

dc.contributor.authorGELMEZ, BÜŞRA
dc.contributor.authorYildiz-Pekoz, Ayca
dc.contributor.authorYÜKSEL, NİLÜFER
dc.date.accessioned2023-10-10T13:09:11Z
dc.date.available2023-10-10T13:09:11Z
dc.date.issued2023
dc.identifier.citationYÜKSEL N., GELMEZ B., Yildiz-Pekoz A., "Lung Microbiota: Its Relationship to Respiratory System Diseases and Approaches for Lung-Targeted Probiotic Bacteria Delivery", MOLECULAR PHARMACEUTICS, sa.7, ss.3320-3337, 2023
dc.identifier.issn1543-8384
dc.identifier.othervv_1032021
dc.identifier.otherav_2d1603fd-192f-4840-a197-c11259921c71
dc.identifier.urihttp://hdl.handle.net/20.500.12627/190461
dc.identifier.urihttps://doi.org/10.1021/acs.molpharmaceut.3c00323
dc.description.abstractMicroorganisms that make up the local microbiota (suchas Lactobacillus sp. and Bifidobacterium sp.)play a crucial role in the modulation of diseases and health statesby taking place not only in the gut but also in many parts of ourbody. There is also interference between the gut and the lung viathe gut-lung axis. The relationship between respiratory diseasesand lung microbiota, which become more of an issue of particular importancein recent years, shows that probiotics play an essential role in maintainingthe balance of microorganisms in the respiratory tract. However, studieson probiotics' prophylactic or therapeutic application in chroniclung diseases are limited. In this review, the literature between1977 and 2022 was surveyed. General information about human microbiotawas accessed in earlier sources, and especially in the past decade,research on lung microbiota has been reached. The relationship betweenlung microbiota and important respiratory diseases such as bronchopulmonarydysplasia, chronic obstructive pulmonary disease, pneumonia, cysticfibrosis, allergy-asthma, influenza, lung cancer, and COVID-19 infection,was scrutinized after mentioning human microbiota, the gut-lungaxis, and respiratory tract microbiota. The mechanism of action ofprobiotics and the formulation approaches of probiotics in terms ofpharmaceutical technology were reviewed. Finally, future perspectiveson lung-targeted administration of probiotic bacteria with prophylacticor therapeutic potential, or both, were presented.
dc.language.isoeng
dc.subjectFarmakoloji, Toksikoloji ve Eczacılık (çeşitli)
dc.subjectGenel Farmakoloji, Toksikoloji ve Eczacılık
dc.subjectAraştırma ve Teori
dc.subjectTIP, ARAŞTIRMA VE DENEYSEL
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectTıp
dc.subjectDahili Tıp Bilimleri
dc.subjectTıbbi Ekoloji ve Hidroklimatoloji
dc.subjectEczacılık
dc.subjectTemel Eczacılık Bilimleri
dc.subjectYaşam Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTemel Bilimler
dc.subjectFarmakoloji
dc.subjectİncelemeler ve Referanslar (tıbbi)
dc.subjectFarmakoloji (tıbbi)
dc.subjectİlaç Rehberleri
dc.titleLung Microbiota: Its Relationship to Respiratory System Diseases and Approaches for Lung-Targeted Probiotic Bacteria Delivery
dc.typeMakale
dc.relation.journalMOLECULAR PHARMACEUTICS
dc.contributor.departmentAnkara Üniversitesi , Eczacılık Fakültesi , Eczacılık Teknolojisi Bölümü
dc.identifier.issue7
dc.identifier.startpage3320
dc.identifier.endpage3337
dc.contributor.firstauthorID4315218


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster